In the Specification:

Please insert the following paragraph at the top of the first page and immediately before "CROSS-REFERENCE TO RELATED APPLICATIONS":

TITLE OF THE INVENTION

Carrier Protein Having an Adjuvant Effect

Please replace the paragraph immediately after "CROSS-REFERENCE TO RELATED APPLICATIONS" with the following:

This application is a division of Application Serial No. 09/679,750, filed 10/05/2000, now US Patent No. 6,780,420, which is a continuation of application Serial No. 08/836,500, filed 08/11/97, now US Patent No. 6,197,929, which is a national stage 371 application of the international application PCT/FR95/01463, which claims foreign priority to application 94,13306 filed 07/11/1994 in France.

Please insert the following heading immediately after the paragraph dealing with "CROSS-REFERENCE TO RELATED APPLICATIONS":

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

Not Applicable

Please insert the following heading immediately after the paragraph dealing with "STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT":

THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT

Not Applicable

Please insert the following heading immediately after the paragraph dealing with "THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT":

REFERENCE TO A "SEQUENCE LISTING"

The application contains "Sequence Listing" in the computer readable form. The computer readable form is identical with that filed in Application Serial No. 08/836,500, filed 08/11/97, now US Patent No. 6,197,929.

Please insert the following heading immediately after the paragraph dealing with "Reference to a "Sequence Listing"":

FIELD OF THE INVENTION

Please insert the following heading immediately after line 9 of page 1 and immediately before line 10 (i.e. the sentence that starts, "The development of vaccines...") of page 1 in the originally submitted translation:

BACKGROUND ART

Please insert the following heading immediately after line 32 of page 1 and immediately before line 33 (i.e. the sentence that starts, "The Applicant has demonstrated...") of page 1 in the originally submitted translation:

SHORT SUMMARY OF THE INVENTION

Please insert the following heading immediately after line 11 of page 6 and immediately before line 12 (i.e. the sentence that starts, "In these examples...") of page 6 in the originally submitted translation:

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Please insert the following heading immediately after line 24 of page 6 and immediately before line 25 (i.e. the sentence that starts, "Example 1: Isolation...") of page 6 in the originally submitted translation:

DETAILED DESCRIPTION OF THE INVENTION

Please replace the paragraph that starts on line 4 of page 7 with the following:

The pellets obtained after the second precipitation are resuspended in a 1% solution of ~~zwittergent~~ Zwittergent® 3-14.

Please replace the paragraph that starts on line 13, page 7 with the following:

The proteins of the MP fraction are dialysed against a 20 mM Tris/HC1, pH 8.0; 0.1% ~~zwittergent~~ Zwittergent ® 3-14 buffer. The dialysate is loaded onto a column

containing a support of the strong anion exchanger type (column of ø = 50 mm x H = 250 mm, Biorad® Macroprep High Q gel) which is equilibrated in the above-described buffer. The P40 protein is eluted at an NaCl concentration of 50 mM in the equilibration buffer.

Please replace the paragraph that starts on line 21, page 7 with the following:

The fractions containing the P40 are pooled and dialysed against a 20 mM citrate, pH 3.0; 0.1% ~~zwittergent~~ Zwittergent ® 3-14 buffer. The dialysate is loaded onto a column containing a support of the strong cation exchanger type (diamensions of the column: ø = 25 mm x H = 160 mm, Biorad® Macroprep High S gel) which is equilibrated in the 20 mM citrate, pH 3.0; 0.1% ~~zwittergent~~ Zwittergent ® 3-14 buffer. The P40 protein is eluted at an NaCl concentration of 0.7 M. The fractions containing the P40 are pooled and concentrated by ultrafiltration using a Minitan® Millipore tangential flow filtration system employing membrane discs having a cutoff threshold of 10 kDa.

Please replace the paragraph that starts on line 9, page 10 with the following:

Gene amplification

Lysis buffer:	25 mM Taps, pH 9.3 2 mM $MgCl_2$
Amplification buffer:	25 mM Taps, pH 9.3 2 mM $MgCl_2$ 0.1% Tween® 20 200 mM dNTP.

Please replace the paragraph that starts on line 16, page 10 with the following:

TST (20x) :	Tris base	0.5 M
	HCl	0.3 M
	NaCl	4 M
	Tween® 20	1%
	EDTA	20 mM

Washing buffer:	Tris HCl	50 mM	pH 8.5
	$MgCl_2$	5 mM	
Denaturation	Gua – HCl	7.8 M	
solution:	Tris-HCl	28 mM	pH 8.5
Renaturation	Gua-HCl	0.5 M	
solution:	Tris-HCl	25 mM	pH 8.5
	NaCl	150 mM	
	Tween® 20	0.05%	

Please replace the paragraph that starts on line 24, page 11 with the following:

These reactions are carried out in 100 µl of amplification buffer using 5 pmol of each primer and 1 unit of Taq polymerase enzyme (Perkin Elmer Cetus). Each cycle comprises one denaturation step of 30 seconds at 95°C, followed by hybridization of the primer to the DNA and an extension of one minute at 72°C. 30 cycles are performed in this way using a Perkin Elmer Cetus "Gen Amp PCR"® 9000 thermocycler.

Please replace the paragraph that starts on line 2, page 12 with the following:

The fragments which have thus been cloned are sequenced on an Applied Biosystems 373 automated DNA Sequencer. The sequencing reactions are carried out using the "Dye Terminator"® kit in accordance with the supplier's (Applied Biosystems) recommendations either on double-stranded DNA obtained after gene amplification or derived from a maxiprep, or on single-stranded DNA drived from denatured PCR fragments (Hultman, T. et al., *1989*, Nucleid Acids Rev. 17: 4937-4946).